Search research articles
Contact Us
Filters
Showing results (1-10 of 13) with videos related to
Page
of 2
Sort By:
Drug Design, Development and Therapy
|
September 24, 2025
Eribulin plus Pyrotinib in Trastuzumab-Resistant, HER2-Positive Advanced Breast Cancer: A Single-Arm, Multicenter Phase II Trial (EPIC Trial)
Ruoyang Li, Meiqi Wang, Xiangshun Kong, et al.
Oncology Letters
|
April 11, 2022
miR-217-5p suppresses epithelial-mesenchymal transition and the NF-κB signaling pathway in breast cancer via targeting of metadherin
Lixian Yang, Shuo Liu, Liu Yang, et al.
Sensors (Basel, Switzerland)
|
May 13, 2023
On-Chip Compressive Sensing with a Single-Photon Avalanche Diode Array
Chenxi Qiu, Peng Wang, Xiangshun Kong, et al.
Virchows Archiv : an International Journal of Pathology
|
March 1, 2017
Expression of Rab5a correlates with tumor progression in pancreatic carcinoma
Yuandong Li, Xiaofang Sun, Donghui Ji, et al.
IEEE Transactions on Pattern Analysis and Machine Intelligence
|
April 29, 2026
Learned Optimal Visual Time-of-Flight Imaging with Fisher Information Guidance
Kanghui Wang, Jiaqu Li, Zhangnan Li, et al.
Translational Breast Cancer Research : a Journal Focusing on Translational Research in Breast Cancer
|
May 16, 2024
A new pathological assessment method to assess residual lesions after neoadjuvant chemotherapy for breast cancer, residual disease in breast and nodes combined with Ki-67 (RDBN-K)
Ruoqi Han, Yanqi Ma, Zhikun Liu, et al.
RSC Advances
|
August 31, 2022
Selenium substituted axitinib reduces axitinib side effects and maintains its anti-renal tumor activity
Ying Fu, Rengui Saxu, Kadir Ahmad Ridwan, et al.
Frontiers in Oncology
|
July 25, 2022
Pegylated Liposomal Doxorubicin, Docetaxel, and Trastuzumab as Neoadjuvant Treatment for HER2-Positive Breast Cancer Patients: A Phase II and Biomarker Study
Haoqi Wang, Yuntao Li, Yixin Qi, et al.
Medicine
|
December 6, 2021
Real-world effectiveness and sensitivity of palbociclib plus endocrine therapy in HR+/HER2- patients with metastatic breast cancer
Jingping Li, Xiangmei Zhang, Chao Yang, et al.
Breast Cancer Research : BCR
|
February 13, 2025
Clinical efficacy and therapy response prediction of neoadjuvant dalpiciclib plus letrozole in postmenopausal patients with HR+/HER2- stage II-III breast cancer (DARLING 01): a single-arm, open-label, exploratory study
Lina Zhang, Yueping Liu, Chao Yang, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 13) with videos related to
Sort By:
Page
of 2
Drug Design, Development and Therapy
|
September 24, 2025
Eribulin plus Pyrotinib in Trastuzumab-Resistant, HER2-Positive Advanced Breast Cancer: A Single-Arm, Multicenter Phase II Trial (EPIC Trial)
Ruoyang Li, Meiqi Wang, Xiangshun Kong, et al.
Oncology Letters
|
April 11, 2022
miR-217-5p suppresses epithelial-mesenchymal transition and the NF-κB signaling pathway in breast cancer via targeting of metadherin
Lixian Yang, Shuo Liu, Liu Yang, et al.
Sensors (Basel, Switzerland)
|
May 13, 2023
On-Chip Compressive Sensing with a Single-Photon Avalanche Diode Array
Chenxi Qiu, Peng Wang, Xiangshun Kong, et al.
Virchows Archiv : an International Journal of Pathology
|
March 1, 2017
Expression of Rab5a correlates with tumor progression in pancreatic carcinoma
Yuandong Li, Xiaofang Sun, Donghui Ji, et al.
IEEE Transactions on Pattern Analysis and Machine Intelligence
|
April 29, 2026
Learned Optimal Visual Time-of-Flight Imaging with Fisher Information Guidance
Kanghui Wang, Jiaqu Li, Zhangnan Li, et al.
Translational Breast Cancer Research : a Journal Focusing on Translational Research in Breast Cancer
|
May 16, 2024
A new pathological assessment method to assess residual lesions after neoadjuvant chemotherapy for breast cancer, residual disease in breast and nodes combined with Ki-67 (RDBN-K)
Ruoqi Han, Yanqi Ma, Zhikun Liu, et al.
RSC Advances
|
August 31, 2022
Selenium substituted axitinib reduces axitinib side effects and maintains its anti-renal tumor activity
Ying Fu, Rengui Saxu, Kadir Ahmad Ridwan, et al.
Frontiers in Oncology
|
July 25, 2022
Pegylated Liposomal Doxorubicin, Docetaxel, and Trastuzumab as Neoadjuvant Treatment for HER2-Positive Breast Cancer Patients: A Phase II and Biomarker Study
Haoqi Wang, Yuntao Li, Yixin Qi, et al.
Medicine
|
December 6, 2021
Real-world effectiveness and sensitivity of palbociclib plus endocrine therapy in HR+/HER2- patients with metastatic breast cancer
Jingping Li, Xiangmei Zhang, Chao Yang, et al.
Breast Cancer Research : BCR
|
February 13, 2025
Clinical efficacy and therapy response prediction of neoadjuvant dalpiciclib plus letrozole in postmenopausal patients with HR+/HER2- stage II-III breast cancer (DARLING 01): a single-arm, open-label, exploratory study
Lina Zhang, Yueping Liu, Chao Yang, et al.
Page
of 2